Literature DB >> 11177667

Is there a role for calcium channel blockers in congestive heart failure?

A B Miller1.   

Abstract

Over the past several decades, we have made great strides in understanding the pathophysiology of heart failure and have developed new therapeutic targets based on utilizing several different models in clinical trials. Currently, standard therapy involves angiotensin-converting enzyme inhibitors and beta-blockers. In an effort to further reduce mortality, investigators focused on other vasodilators (calcium channel blockers) that might prove to be advantageous when added to standard therapy. Large- scale trials showed that the calcium channel blockers did not have a specific role in mortality reduction, but the third-generation dihydropyridine calcium channel blockers were safe to use in patients with heart failure.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11177667     DOI： 10.1007/s11886-001-0036-7

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  19 in total

1.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

Authors:  J N Cohn; G Johnson; S Ziesche; F Cobb; G Francis; F Tristani; R Smith; W B Dunkman; H Loeb; M Wong
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

2.  A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure.

Authors:  U Elkayam; J Amin; A Mehra; J Vasquez; L Weber; S H Rahimtoola
Journal:  Circulation       Date:  1990-12       Impact factor: 29.690

3.  Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.

Authors:  J N Cohn; S Ziesche; R Smith; I Anand; W B Dunkman; H Loeb; G Cintron; W Boden; L Baruch; P Rochin; L Loss
Journal:  Circulation       Date:  1997-08-05       Impact factor: 29.690

4.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

Authors: 
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

5.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.

Authors:  M Packer; C M O'Connor; J K Ghali; M L Pressler; P E Carson; R N Belkin; A B Miller; G W Neuberg; D Frid; J H Wertheimer; A B Cropp; D L DeMets
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

6.  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Authors: 
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

7.  Beneficial effects of nifedipine on rest and exercise myocardial energetics in patients with congestive heart failure.

Authors:  R D Magorien; C V Leier; A J Kolibash; T J Barbush; D V Unverferth
Journal:  Circulation       Date:  1984-11       Impact factor: 29.690

8.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.

Authors:  M Packer; J R Carver; R J Rodeheffer; R J Ivanhoe; R DiBianco; S M Zeldis; G H Hendrix; W J Bommer; U Elkayam; M L Kukin
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

9.  Sublingual nifedipine: acute effects in severe chronic congestive heart failure secondary to idiopathic dilated cardiomyopathy.

Authors:  A B Miller; D A Conetta; T A Bass
Journal:  Am J Cardiol       Date:  1985-05-01       Impact factor: 2.778

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.